1921
Volume 101, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Intravenous (IV) dexamethasone is recommended for 14 days in stage 1 and 28 days in stage 2/3 tuberculous meningitis (TBM). We used a different steroid protocol. We shifted TBM patients to oral steroids after 48 hours of sustained improvement on IV steroids (oral group). Patients who worsened after shifting to oral steroids were reinitiated on IV steroids. Once they showed a consistent improvement for 48 hours, the IV steroids were overlapped with oral steroids for 7–10 days to taper off IV steroids (overlap group). We compared total IV steroid days in our patients with the recommended treatment and identified predictors that favored the oral group. This was a retrospective study. We included 98 patients with TBM (66 in the overlap group and 32 in the oral group) from January 2013 to July 2018. The median IV steroid days were 9 days (interquartile range of 4–12; 2–3.5 days in the oral group and 10–11.5 days in the overlap group). The mortality rate was 6.1%. The logistic regression model showed that TBM patients with basal exudate, tuberculoma, and modified Rankin scale (mRS) < 3 had a higher probability for going to the oral group. We conclude that total IV steroid days can be reduced in TBM patients by our method of steroid use. Presence of basal exudates and tuberculoma may favor early shifting from IV to oral steroid, whereas higher mRS may require a relatively longer course of IV steroid.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0416
2019-09-16
2020-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/5/tpmd190416.html?itemId=/content/journals/10.4269/ajtmh.19-0416&mimeType=html&fmt=ahah

References

  1. Prasad K, Singh MB, Ryan H, 2016. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 4: 164.
    [Google Scholar]
  2. Thwaites GE et al., 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351: 17411751.
    [Google Scholar]
  3. Marais S, Thwaites G, Schoeman JF, Torok ME, Misra UK, Prasad K, Donald PR, Wilkinson RJ, Marais BJ, 2010. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 10: 803812.
    [Google Scholar]
  4. Chiang SS, Khan FA, Milstein MB, Tolman AW, Benedetti A, Starke JR, Becerra MC, 2014. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 14: 947957.
    [Google Scholar]
  5. Wang JT, Hung CC, Sheng WH, Wang JY, Chang SC, Luh KT, 2002. Prognosis of tuberculous meningitis in adults in the era of modern antituberculous chemotherapy. J Microbiol Immunol Infect 35: 215222.
    [Google Scholar]
  6. Hosoglu S et al., 2002. Predictors of outcome in patients with tuberculous meningitis. Int J Tuberc Lung Dis 6: 6470.
    [Google Scholar]
  7. Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH, 1998. Tuberculous meningitis in South African urban adults. QJM 91: 743747.
    [Google Scholar]
  8. Lamprecht D, Schoeman J, Donald P, Hartzenberg H, 2001. Ventriculoperitoneal shunting in childhood tuberculous meningitis. Br J Neurosurg 15: 119125.
    [Google Scholar]
  9. Kalita J, Misra UK, Ranjan P, 2007. Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol 14: 3337.
    [Google Scholar]
  10. Sharma SK et al., 2017. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian J Med Res 145: 448463.
    [Google Scholar]
  11. World Health Organization, 2017. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update. Available at: http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1. Accessed September 17, 2018.
    [Google Scholar]
  12. Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R, 2009. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol 103: 625634.
    [Google Scholar]
  13. Chotmongkol V, Jitpimolmard S, Thavornpitak Y, 1996. Corticosteroid in tuberculous meningitis. J Med Assoc Thai 79: 8390.
    [Google Scholar]
  14. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR, 1997. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 99: 226231.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0416
Loading
/content/journals/10.4269/ajtmh.19-0416
Loading

Data & Media loading...

Supplemental tables and figure

  • Received : 31 May 2019
  • Accepted : 16 Aug 2019
  • Published online : 16 Sep 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error